Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer

@inproceedings{Komatsu2015StudyPO,
  title={Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer},
  author={Yoshito Komatsu and Chikashi Ishioka and Ken Shimada and Yasuhide Yamada and Makio Gamoh and Atsushi Sato and Tatsuro Yamaguchi and Satoshi Yuki and Satoshi Morita and Shin Takahashi and Rei Goto and Minoru Kurihara},
  booktitle={BMC Cancer},
  year={2015}
}
Metastatic colorectal cancer carries a poor prognosis and cannot be cured by currently available therapy. Chemotherapy designed to prolong survival and improve the quality of life (QOL) of patients is the mainstay of treatment. Standard regimens of FOLFOX/bevacizumab and CapeOX/bevacizumab can cause neurotoxicity, potentially disrupting treatment. The… CONTINUE READING